$ARVN was mentioned 11 times over the past 12 months by 2 distinct FinTwit voices, with the first mention on September 17, 2025, and the most recent on May 12, 2026. Jacob Plieth (@jacobplieth) dominated the conversation with 11 mentions, while Adam Feuerstein (@adamfeuerstein) contributed 5 mentions. The majority of discussion centered on biotech-related topics.

Recent activity focused on regulatory developments and commercialization plans for $ARVN's vepdegrestrant. In early May 2026, the FDA approved the compound ahead of its June 5 PDUFA date. The company faced questions about its commercialization strategy, with Adam Feuerstein noting on May 1 that $ARVN and partner $PFE had not yet disclosed selection of a third-party commercialization partner. By May 12, Rigel Pharmaceuticals announced it would handle commercialization of Veppanu for both $ARVN and $PFE under what Feuerstein described as "modest financial terms."